<?xml version="1.0" encoding="UTF-8"?>
<p id="p0210">While progress is being made in vaccines to combat AMR, GVIRF participants cautioned that awareness and acceptance of this approach remains a challenge and called on one another to: define and communicate the value of vaccines to combat AMR; identify populations who would benefit most; and consider affordability and accessibility in low- and middle-income countries.</p>
